Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cirrhosis
68%
Cirrhotic Patients
52%
Objective Structured Clinical Examination
39%
Portal Hypertension
38%
Nonalcoholic Steatohepatitis
35%
Taiwan
34%
Intrahepatic Resistance
30%
Portal Pressure
28%
Medical Students
23%
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
22%
Tumor Necrosis Factor-α
21%
Liver
18%
Primary Biliary Cirrhosis
17%
Hemodynamic Effects
17%
Examination Performance
17%
Hepatic Steatosis
16%
Interprofessional Collaboration
16%
Bile Duct
15%
Postgraduate Year
14%
Hepatic Microcirculation
14%
Ascites
14%
Metabolic
14%
Hepatic Venous Pressure Gradient
13%
Liver Cirrhosis
13%
Fatty Liver
13%
Virtual Reality
13%
Competencies
13%
Bile Duct Ligation
12%
Propranolol
12%
Aliskiren
12%
Steatotic Liver Disease
12%
High-fat Diet
11%
Cirrhotic Liver
11%
Peroxisome Proliferator-activated Receptor
11%
Thalidomide
11%
Visceral Adipose Tissue
11%
Chronic Pulmonary Aspergillosis
10%
Thromboxane A2 (TXA2)
10%
Steatohepatitis
10%
Protective Effect
10%
Hepatocellular Carcinoma
10%
Acute Kidney Injury
10%
Bacterial Infection
10%
Angiogenesis
10%
Prospective Cohort Study
10%
Endocannabinoids
9%
Hepatic Endothelial Dysfunction
9%
Clinical Performance
9%
Interprofessional Teams
9%
Collaborative Coefficient
9%
Pharmacology, Toxicology and Pharmaceutical Science
Rat
100%
Liver Cirrhosis
54%
Fatty Liver
37%
Nonalcoholic Fatty Liver
36%
Portal Hypertension
30%
Tumor Necrosis Factor
23%
Biliary Cirrhosis
17%
Liver Fibrosis
13%
Inflammation
13%
Propranolol
12%
Choline
11%
Methionine
11%
Anandamide
11%
Endocannabinoid
11%
Endothelial Dysfunction
10%
Cytokine
9%
Liver Injury
9%
Aliskiren
9%
Peroxisome Proliferator Activated Receptor
9%
Fibrosis
9%
Nutritional Deficiency
8%
Liver Disease
8%
Endotoxemia
8%
Cannabinoid
8%
Thalidomide
7%
Cohort Study
7%
Lipid
7%
Insulin Resistance
7%
Octreotide
7%
Endothelin 1
6%
Thromboxane A2
6%
Ascites
6%
Terlipressin
6%
Receptor
6%
Pathogenesis
6%
Cannabinoid 1 Receptor
6%
Hepatorenal Syndrome
6%
Muscle Atrophy
6%
Losartan
6%
Bacterial Infection
6%
Decoy Receptor 3
6%
Elafibranor
6%
Salvia Miltiorrhiza
6%
Obeticholic Acid
6%
Carbon Tetrachloride
6%
Adenosine
6%
Fat Droplet
6%
Portopulmonary Hypertension
6%
Sildenafil
6%
Rat Model
6%
Medicine and Dentistry
Liver Cirrhosis
53%
Clinical Examination
27%
Nonalcoholic Fatty Liver
26%
Portal Venous Pressure
23%
Portal Hypertension
21%
Medical Student
21%
Fatty Liver
20%
Hemodynamic
20%
Tumor Necrosis Factor
19%
Liver Disease
13%
Receptor
13%
Inflammation
13%
Bile Duct
13%
Steatohepatitis
12%
Education
12%
Vasodilatation
11%
Microcirculation
11%
Metabolic Dysfunction-Associated Steatotic Liver Disease
11%
Gut
11%
Oxidative Stress
10%
Angiogenesis
10%
Platelet
10%
Venous Pressure
10%
Ascites
10%
Liver Injury
9%
Hepatocellular Carcinoma
9%
Aliskiren
9%
Propranolol
9%
Adipose Tissue
9%
In Vitro
9%
Endothelial Dysfunction
8%
Prediction Model
8%
Endocannabinoid
8%
Nitric Oxide
8%
Internal Medicine
8%
Vasculotropin
7%
Sodium
7%
Anandamide
7%
Self-Directed Learning
7%
Biliary Cirrhosis
7%
Genetics
7%
Endothelin 1
6%
Monocyte
6%
Insulin Resistance
6%
Cohort Analysis
6%
Acute Kidney Injury
6%
Lung Function
6%
Bone Density
6%
Retrospective Study
6%
Model for End-Stage Liver Disease
6%
